Role of bone morhogenetic proteins 4 in the human brain glioma cell line U251

Abstract

Objective To to investigate the role of bone morhogenetic proteins 4 (BMP4) in the human brain glioma cell line U251. Methods Adriamycin or plasmid of BMP4 was given to U251 cells, and BMP4 siRNA was given to U251 cells which had been given adriamycin for 48 h. Methyl thiazolyl tet-razolium ( MTT) was used to measure the activity of U251 cell growth in control group and treatment group. By the formula (1-Atreatment group/Acontrol group) ×100% , U251 cells growth inhibition rate was calculated. By using reverse transcription-polymerase chain reaction ( RT-PCR) , fluorescence quantitative PCR (FQ-PCR) and Western blotting, the transfection efficiency and the expression of BMP4 were assayed. Results Transfection was proved to be successful by RT-PCR, quantitative fluorescent PCR and Western blotting. Growth inhibition rate of U251 cells which were given BMP4 plasmid was (23.4± 1.1)%, (54.8±1.3)%, (58.8 ±1.6)%,(57.2 ±1.4)%, (56.1±0.9)% at the 0.5, 1.0, 1.5, 2. 0, 2. 5μg/well. There was significant difference in inhibition rate between 0. 5μg/well group and 1.0, 1.5, 2.0, 2.5μg/well groups (P 0.05). After adriamycin was added to U251 cells, the inhibition rate was (45. 2 ± 1. 1) % (P <0. 05 ). After BMP4 siRNA was added to U251 cells which had been given adriamycin , the inhibition rate of cells was (23.1± 2.7) % (P<0.05). Conclusion BMP4 can inhibit the glioma cells U251. BMP4 may be a new target for glioma therapy. Key words: Bone morphogenetic protein 4; Target therapy; Glioma